— including the U.S. FDA, EMA, and MHRA — emphasize that sponsors are responsible for verifying site capabilities and ensuring timely activation under ICH E6(R3) Good Clinical Practice.

Delays or weaknesses in feasibility and start-up often cascade into protocol deviations, budget overruns, and missed milestones.

This comprehensive guide outlines the regulatory requirements, operational strategies, and documentation standards for effective site feasibility and start-up management in modern clinical research.

Understanding the Importance of Site Feasibility

Site feasibility assessment is a systematic process of evaluating a potential investigator site’s suitability for participating in a specific clinical trial.

It helps sponsors and CROs identify facilities that have the right patient population, resources, infrastructure, and experience to deliver reliable data on schedule.

Objectives of feasibility assessment:

• Assess site experience with similar therapeutic areas and study phases.
• Evaluate patient pool, recruitment rate, and historical enrollment performance.
• Review investigator credentials, licenses, and GCP training certifications.
• Confirm availability of equipment, labs, and storage facilities for investigational products.
• Identify potential operational or logistical barriers.

Conducting a detailed feasibility analysis helps avoid costly site terminations or delays.

According to a 2024 Tufts CSDD report, nearly 37% of global trial delays originate from inadequate feasibility and start-up planning — a clear indicator of its strategic importance.

Regulatory Expectations for Feasibility and Site Qualification

Regulatory authorities expect sponsors to have documented procedures for evaluating and qualifying investigator sites before initiation.

The ICH E6(R3) guideline requires sponsors to verify investigator qualifications, site facilities, and the ability to comply with GCP, protocol, and applicable regulations.

FDA 21 CFR 312.53(a): mandates that sponsors “select only investigators qualified by training and experience” and “ensure proper monitoring and oversight.”

Similarly, EU-CTR 536/2014 and MHRA GCP Guide require sponsors to maintain documented evidence of site assessment, feasibility outcome, and investigator authorization before study start.

Typical regulatory documentation:

• Investigator CVs, licenses, and training certificates.
• Completed Site Feasibility Questionnaire (SFQ) and supporting data.
• Facility and equipment qualification reports.
• IRB/EC approvals of the site and investigator.
• Site Qualification Visit (SQV) reports signed by monitors.

Each of these documents must be filed within the Trial Master File (TMF) and Investigator Site File (ISF) as evidence of pre-study qualification.

Failure to maintain these records can result in FDA Form 483 observations or MHRA critical findings during inspection.

Designing and Using Site Feasibility Questionnaires (SFQs)

The Site Feasibility Questionnaire is the backbone of the feasibility process.

It collects critical data points on site operations, patient demographics, staff expertise, and regulatory experience to guide site selection decisions.

Key sections of an SFQ include:

• Investigator information — qualifications, experience, and contact details.
• Previous trial experience and therapeutic area exposure.
• Infrastructure details — storage, laboratories, emergency facilities.
• Patient pool and recruitment projection data.
• Ethics committee processes and IRB submission timelines.
• Technology readiness — access to EDC, eTMF, IRT, and remote monitoring systems.

To ensure data reliability, feasibility questionnaires should be reviewed by trained CRAs or Clinical Project Managers, with follow-up discussions to verify accuracy.

Sites providing unrealistic recruitment projections or incomplete operational details should undergo additional qualification checks before selection.

Site Qualification and Pre-Study Visits (PSVs)

Once potential sites are shortlisted, the next step is conducting Site Qualification Visits (SQVs), also known as Pre-Study Visits (PSVs).

These visits confirm that the site’s personnel, facilities, and procedures meet protocol and GCP requirements before the study begins.

Objectives of SQV:

• Validate investigator credentials and training status.
• Inspect site infrastructure, including storage conditions and calibration records.
• Review IRB/EC submission readiness and institutional policies.
• Evaluate clinical and laboratory systems for data integrity and security.
• Discuss recruitment strategies, staffing, and study-specific roles.

The SQV should be documented in a detailed report signed by both the CRA and PI.

Any identified gaps must be addressed through pre-initiation CAPAs before site activation.

A standardized Site Qualification Checklist ensures consistency across global study teams.

Regulatory Submissions and Ethics Approvals

Site activation cannot proceed without successful submission and approval of regulatory and ethics documents.

Sponsors must ensure alignment between local regulations and global requirements for all submission packages.

Common submission components:

• Protocol and Investigator Brochure (IB).
• Informed Consent Form (ICF) with translated versions, where required.
• Insurance and indemnity documentation.
• Curricula vitae and licenses for all investigators.
• IRB/EC approval letters and meeting minutes.
• Regulatory authority acknowledgments (e.g., FDA IND or EU CTA numbers).

Under EU-CTR 536/2014, submissions occur through the Clinical Trials Information System (CTIS), ensuring transparency and harmonization across member states.

In the U.S., all site documents must align with the FDA IND submission framework under 21 CFR Part 312.

Tracking submission timelines and maintaining version control are essential for inspection readiness and compliance documentation.

Contract Negotiation and Budget Finalization

Parallel to the regulatory process, the sponsor or CRO must finalize contracts and budgets with each participating site.

These agreements define financial terms, scope of services, indemnification, and confidentiality obligations.

Essential contract elements:

• Payment schedules and milestone-based disbursements.
• Compensation for subject visits, data entry, and archiving activities.
• Liability coverage and indemnity clauses for sponsor and investigator.
• Ownership of study data and publication rights.
• Compliance with anti-bribery and transparency laws (e.g., Sunshine Act, EFPIA Disclosure Code).

Delays in contract negotiation are among the top three causes of start-up bottlenecks.

Sponsors should employ standardized contract templates and pre-approved budget frameworks to accelerate site activation.

All executed contracts must be filed in the TMF and linked to the investigator’s regulatory binder.

Site Initiation Visit (SIV) and Activation

The Site Initiation Visit (SIV) marks the transition from preparation to execution.

It confirms that all pre-study activities — training, documentation, and equipment setup — have been completed and that the site is ready to recruit subjects.

Key activities during SIV:

• Comprehensive investigator and staff training on protocol and GCP.
• Review of essential document completeness and version control.
• Verification of IMP receipt, accountability logs, and storage conditions.
• Confirmation of IRB/EC and regulatory approvals.
• Review of safety reporting procedures and contact information.

The CRA should document the SIV outcome in a formal report, signed by the investigator, confirming readiness for first patient enrollment.

Regulators frequently request SIV reports during inspections as proof that study initiation was controlled and compliant.

Timelines, Metrics, and Performance Tracking

Efficient study start-up requires disciplined project management.

Sponsors should establish Key Performance Indicators (KPIs) and Key Start-Up Metrics (KSMs) to monitor progress and identify bottlenecks across global sites.

Common start-up metrics include:

• Average time from site selection to SIV completion.
• Cycle time for contract execution and regulatory approval.
• Number of protocol or ICF amendments before activation.
• Rate of document query resolution within eTMF.
• Percentage of sites activated within target timelines.

Regular performance dashboards and centralized oversight meetings enable proactive risk mitigation.

Integration of CTMS, eTMF, and Regulatory Information Management (RIM) systems provides real-time visibility and accelerates decision-making.

Technology-Enabled Start-Up Optimization

Digital tools have revolutionized the start-up process by automating repetitive tasks, improving accuracy, and enhancing collaboration across time zones.

Adoption of technology platforms helps sponsors achieve both speed and compliance.

Key innovations driving start-up transformation:

• Feasibility intelligence platforms for pre-screening sites using historical performance data.
• eFeasibility forms that auto-validate entries and integrate with CTMS databases.
• Electronic regulatory submission systems like CTIS, IRAS (U.K.), and FDA’s ESG for secure document exchange.
• AI-driven contract review tools that reduce negotiation cycles.
• Virtual Site Initiation Visits (vSIVs) enabling hybrid trial launch models.

However, technology adoption must remain compliant with 21 CFR Part 11, GDPR, and ICH E6(R3) expectations for data integrity and system validation.

Every electronic system used in feasibility or start-up must have a documented validation report and training record in the TMF.

Risk Management During Study Start-Up

Start-up is one of the highest-risk phases of a trial because it involves multiple stakeholders, document exchanges, and regulatory dependencies.

Sponsors must identify and control potential delays and quality issues using a risk-based approach.

Key risks and mitigation strategies:

• Delayed regulatory approval: Initiate early engagement with IRBs/ECs and maintain pre-submission checklists.
• Inconsistent feasibility data: Implement CRA verification calls and cross-check patient availability metrics.
• Contract negotiation bottlenecks: Use standardized templates and predefined approval hierarchies.
• Unqualified staff or incomplete training: Mandate certification verification before SIV.
• Document management gaps: Conduct interim TMF reviews to prevent backfilling.

Risk logs and mitigation plans should be reviewed bi-weekly during start-up.

Tracking issues through CAPA workflows within the QMS helps maintain control and continuous improvement.

FAQs — Site Feasibility and Study Start-Up

1. What is the difference between feasibility and qualification?

Feasibility evaluates whether a site is capable of conducting a specific study, while qualification confirms readiness through documented verification and on-site inspection.

2. How early should feasibility activities begin?

Feasibility should begin at least 4–6 months before protocol finalization to allow adequate time for site assessment, budgeting, and regulatory alignment.

3. Which systems are essential for study start-up automation?

Integration of CTMS, eTMF, RIM, and contract management platforms ensures visibility and process control from site identification to activation.

4. How can sponsors improve global feasibility data consistency?

By implementing standardized Feasibility Questionnaires, training CRAs on objective scoring, and centralizing data in validated global databases.

5. What are the top causes of start-up delays?

Delayed IRB/EC approvals, prolonged contract negotiations, incomplete essential documents, and unrealistic site recruitment projections are the most common reasons.

6. How is feasibility linked to risk-based monitoring?

Accurate feasibility data feeds into Risk-Based Monitoring (RBM) models by identifying high-risk sites and setting thresholds for critical parameters early in the trial.

Final Thoughts — Foundation of Compliance and Speed

Effective site feasibility and study start-up are the foundation of every successful clinical trial.

For clinical operations professionals in the U.S., U.K., and EU, balancing speed with compliance defines operational excellence and regulatory confidence.

Each site must be evaluated not only for performance capability but also for ethical standards, data integrity, and patient care quality.

When feasibility and start-up are executed with precision — supported by technology, collaboration, and proactive oversight — the result is a trial that begins right and ends strong.

In clinical research, a well-prepared start is more than a milestone; it is the assurance of safety, reliability, and global credibility.